Loading...
•
Jun 30
Sanara MedTech Q2 2025 Earnings Report
Sanara MedTech reported a narrower net loss in Q2 2025 as revenue grew 28% year-over-year, driven by strong sales of soft tissue repair and bone fusion products.
Key Takeaways
Sanara MedTech's Q2 2025 performance showed notable revenue growth and gross margin improvement, supported by robust product demand in the surgical segment. Despite ongoing investments in the THP segment, losses narrowed compared to the prior year.
Revenue grew 28% YoY to $25.8 million, driven by strong performance in soft tissue repair products.
Net loss narrowed to $2.0 million from $3.5 million in Q2 2024.
Operating loss decreased significantly to just $31,000 from $2.9 million last year.
Adjusted EBITDA rose to $2.7 million, up from $0.6 million in Q2 2024.
Sanara MedTech
Sanara MedTech
Sanara MedTech Revenue by Segment
Sanara MedTech Revenue by Geographic Location
Revenue by Segment
Soft Tissue Repair Revenue
CapyFin.comBone Fusion Products Revenue
CapyFin.comSaaS Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Sanara expects continued strong sales in its surgical segment while evaluating strategic alternatives for its THP unit, with a projected $5.5M–$6.5M cash investment in THP in H2 2025.
Positive Outlook
- Strong sales momentum expected in Sanara Surgical segment.
- Continued product demand for CellerateRX and BIASURGE.
- Improved gross margins to be maintained.
- Expansion into new medical facilities anticipated.
- Ongoing development of product enhancements.
Challenges Ahead
- High cash burn projected for THP initiatives in H2 2025.
- Evaluation of strategic alternatives for THP introduces uncertainty.
- Interest expense continues to pressure bottom line.
- Segment loss in THP expected to persist.
- General cost structure remains elevated due to R&D and SG&A.
Revenue & Expenses
Visualization of income flow from segment revenue to net income